Best of ASCO - 2014 Annual Meeting

 

Welcome

HER2-Positive

Breast Cancer—Metastatic

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).

Akihiko Shimomura

TPS1100

A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer.

Shanu Modi

TPS1102

A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).

Binghe Xu

1026

Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).

Qiang Zhang

1036

Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.

Cornelius F. Waller

1021

B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

Martine J. Piccart-Gebhart

TPS1101

Changing trends in HER-2 neu positive breast cancers in women: A study by a medical student and his preceptor.

Aaron Monga

e12509

Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.

Zachary William Neil Veitch

1034

Combining denosumab (D) and trastuzumab (T) as a novel treatment strategy in HER2-positive (+) breast carcinomas (BC).

Michalis Karamouzis

e12506

Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.

Inna Y. Gong

1037

Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.

Abby Statler

1032

Effect of additional administration of pertuzumab for the post-treatment in patients with HER2-positive locally advanced/metastatic breast cancer who were previously treated with pertuzumab.

Shinichiro Kubo

e12500

Effect of HER2/neu 655 polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.

Isabel Blancas

1025

Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.

Prashanth Reddy Moku

1031

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sandra M. Swain

1020

Estrogen receptor (ER) status and survival outcomes in HER2 positive (+) metastatic breast cancer (mBC).

Karen DeSouza

e12503

Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

Ian E. Krop

1012

HD201: Analytical biocomparability and clinical trial progression of trastuzumab.

Jocelyn hii

e12505

HER2 testing: Insights from pathologists’ perspective on challenging HER2 cases.

Erin V Grimm

e12512

High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).

Jeffrey L. Nordstrom

1030

Impact of mastectomy in women with stage IV HER2+ breast cancer.

Arslan Babar

e12515

Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.

Giuseppe Buono

e12507

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.

Wang Xiao Jia

e12502

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Cristina Saura

1002

Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy.

Sribalaji Lakshmikanthan

e12513

Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.

Irene Kang

e12508

Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.

Zefei Jiang

1001

Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis.

Abby Statler

1033

Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.

Fei Ma

1035

Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer.

William Jeffery Edenfield

e12510

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

Hope S. Rugo

1000

Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.

Laura Spring

1028

Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.

Elena Shagisultanova

1029

Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion.

Kritika Yadav

e12511